AT&T Inc’s Warner Bros. film studio on Thursday postponed the arrival of Christopher Nolan spine chiller “Precept” for a second time due to the coronavirus flare-up, managing another difficulty to the business’ expectations for a pre-fall bounce back.
“Precept” is presently planned to arrive at films on August 12, the organization said in an announcement. Most U.S. cinemas stay shut to help forestall the spread of the pandemic.
It comes as there has been an ongoing flood in coronavirus cases in a few U.S. states.
“Warner Bros. is focused on bringing ‘Principle’ to crowds in theaters, on the big screen, when exhibitors are prepared and general wellbeing authorities state now is the right time,” a representative said.
“Principle” is one of the large spending motion pictures that theater administrators are depending on to bait crowds back to films following an overall shutdown prior this year.
The film is a sci-fi spy dramatization featuring John David Washington and Robert Pattinson from the British executive of hits like “The Dark Knight Rises” and “Commencement.” Little has been uncovered about the plot. The film had initially been planned to make a big appearance on July 17.
Large film chains including AMC Entertainment, Cineworld and Cinemark have said they plan for across the board reopenings of multiplexes in July.
However, authorities in Los Angeles and New York, the best two moviegoing markets in the U.S., have not given a green light for theaters to welcome back guests.
Hollywood studios need whatever number areas open as could be expected under the circumstances to make back their interests in large spending motion pictures. Theater participation will be restricted to uphold social-separating necessities, and it is muddled how agreeable crowds will be with returning.
Around 780 indoor cinemas are at present open in the U.S., as per following firm Comscore.
Warner Bros. said it intended to keep “Precept” in theaters “over an all-encompassing play period a long ways past the standard” after its presentation.
